Jazz Pharmaceuticals (JAZZ) PT Raised to $214 at Jefferies After Mixed Earnings Report
Tweet Send to a Friend
Jefferies analyst David Steinberg raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $214.00 (from $209.00) after Q4 revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
